C4 Therapeutics (CCCC): Analyst $13 Target Points to Potential +300% Upside

Key Takeaways

• The central $13 target is the rounded arithmetic mean of the verified individual analyst price targets reviewed, which produced an average of roughly $12.86.
• With CCCC shares trading near $3.21, reaching $13 would require a rise of roughly 300%, an extremely large move by any conventional measure.
• The analyst target range is unusually wide, spanning from about $7 to $30, reflecting deep uncertainty around early-stage clinical data.
• The strongest supporting factors are the cemsidomide multiple myeloma program, a Roche partnership, and a cash position that funds operations into 2028.
• The biggest risks are clinical setbacks, regulatory hurdles, heavy cash burn, and possible dilution for a pre-profit biotech.
• For more on the ticker's Major News, Today's Price Move, Forecast, and Earnings, explore these additional pages for a fuller market picture.
• Explore Trending AI Robots to see AI-driven tools monitoring stocks like this one.

Analyst Price Targets and Consensus View

C4 Therapeutics, Inc. (CCCC), a clinical-stage biopharmaceutical company focused on targeted protein degradation, carries a wide and unusually dispersed set of analyst price targets. Reviewing the individual, currently cited targets—including J.P. Morgan's Overweight initiation at $10 (October 2026), Wells Fargo's reiteration at $10, Barclays at $7, Guggenheim's initiation at $7 (October 2026), Evercore ISI at $12, Jefferies at $14, and a high estimate near $30—yields a range of roughly $7 to $30 and an arithmetic mean of about $12.86, rounded to a $13 central target.

That dispersion matters. It reflects how differently analysts probability-weight the same early-stage pipeline. The gap between the lowest and highest targets signals that no single "analyst consensus" figure should be treated as a forecast, only as a midpoint of divergent views. J.P. Morgan's initiation highlighted the lead asset cemsidomide in relapsed/refractory multiple myeloma, arguing the shares are undervalued on the fourth-line opportunity alone. Evercore ISI raised its target from $7 to $12 in June 2026. These revisions reflect enthusiasm about clinical catalysts rather than near-term earnings, which remain negative. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Current Market Position and Path Toward the Target

At a recent price near $3.21, moving to $13 implies roughly 300% upside—an exceptionally large move, consistent with a high-risk, pre-revenue-stage biotech whose value hinges almost entirely on clinical outcomes. The company trades well off its 52-week range of roughly $1.69 to $5.17, with trailing twelve-month revenue near $35 million and a net loss exceeding $100 million. There is no P/E (price-to-earnings) multiple to anchor valuation; instead, the shares are priced on the probability-weighted value of pipeline assets.

A path toward the target would likely require successive positive data readouts—first from the phase 2 MOMENTUM study and phase 1b combination studies of cemsidomide—alongside execution of the Roche collaboration on degrader-antibody conjugates announced in April 2026, which carries potential milestone payments above $1 billion.

What Could Support a Move Toward the Target

• Lead asset momentum: cemsidomide, a next-generation CELMoD, is advancing in multiple myeloma, with data catalysts expected across 2026–2027.
• Partnership validation: The Roche collaboration provides non-dilutive funding and external validation of the degrader platform.
• Balance sheet: Cash of roughly $254 million (most recent quarter) supports operations into 2028, reducing near-term dilution risk.
• Positive analyst revisions: Several firms have initiated or raised targets over the past year, reflecting improving conviction in the science.

What Could Prevent the Target From Being Reached

• Clinical and safety risk: Early-stage degrader programs can fail on efficacy or tolerability, collapsing probability-weighted value.
• Cash burn and dilution: With persistent operating losses, future capital raises could pressure the share price.
• Timeline risk: Definitive data is still years away, leaving the stock vulnerable to sentiment shifts and sector rotation.
• Valuation dispersion: The $7-to-$30 range shows analysts themselves disagree sharply on the pipeline's true worth.

Technical Levels and Market Structure

The shares have traded in a broad range, with the 52-week high near $5.17 serving as a notable resistance zone and the $1.69 low as major support. The stock remains far below its September 2021 all-time high near $51, and the current price sits mid-range after a roughly 68% year-to-date advance. A sustained move above $5 would need to clear the 52-week high before any longer-term uptrend toward double digits could be contemplated, and there is no meaningful chart history near $13 to serve as a guidepost. From what I see, reviewing technical patterns with Tickeron’s AI Real Time Patterns can add useful context here.

Time Horizon and What Investors Should Monitor

Analyst price targets generally reflect a research horizon of roughly 12 months, though for early-stage biotechs the relevant catalysts often stretch beyond that window. Investors should watch the next quarterly earnings report, clinical data from the cemsidomide studies, progress and milestone payments under the Roche agreement, any analyst target revisions, and cash-burn and runway disclosures. Regulatory decisions and financing activity will also shape the path toward or away from the target. I’m watching this closely as the next data readouts could shift the probability-weighted outlook meaningfully.

Integrating AI Tools Into My Research

In my own work, I turn to Tickeron’s AI Daily Buy/Sell Signals to supplement fundamental analysis on names like CCCC. These signals use artificial intelligence to monitor market conditions and technical behavior across thousands of stocks, helping surface potential shifts that might otherwise take hours to identify manually. It is a practical way to stay organized when following clinical-stage names with wide valuation ranges.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Contributor

Sergey Savastiouk|Expert

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.

Notable companies

Industry description

Market Cap

High and low price notable news

Volume